SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, a clinical-stage biotechnology company incubated by Third Rock Ventures to develop a new generation of medicines for cardiometabolic diseases, launched today with $190 million in combined Series A and B financings. The Series A round was led by Third Rock Ventures and the Series B round was led by Sofinnova Investments and co-led by Forbion, Perceptive Xontogeny Venture Fund and venBio, with the participation of Alpha Wave Global, Omega Funds, Surveyor Capital (a Citadel company) and founding investor Third Rock Ventures.

加利福尼亚州南旧金山（商业新闻短讯）--Marea Therapeutics是一家临床阶段的生物技术公司，由第三摇滚风险投资公司（Third Rock Ventures）孵化，旨在开发新一代治疗心脏代谢疾病的药物，今天以1.9亿美元的a系列和B系列联合融资推出。A轮由Third Rock Ventures牵头，B轮由Sofinnova Investments牵头，Forbion、Perceptive Xontogeny Venture Fund和venBio共同牵头，Alpha Wave Global、Omega Funds、Surveyor Capital（Citadel公司）和创始投资者Third Rock Ventures参与。

This financing will fund the company’s MAR001 Phase 2 development plan and further progression of additional pipeline programs..

该融资将为公司的MAR001第二阶段开发计划和其他管道项目的进一步进展提供资金。。

“Marea aims to transform the way cardiometabolic diseases are treated by leveraging large-scale human genetics and expertise in adipose function and biology to pursue genetically validated targets focusing on central - but unaddressed - drivers of cardiometabolic disease risk,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea.

Marea首席执行官Josh Lehrer，M.D.，M.Phil，FACC说：“Marea旨在通过利用大规模人类遗传学和脂肪功能和生物学方面的专业知识来改变心脏代谢疾病的治疗方式，以追求经过基因验证的目标，重点关注心脏代谢疾病风险的核心驱动因素，但尚未解决。”。

“This approach could be the next frontier for patients with cardiometabolic disease who remain at very high risk, despite currently available therapies.”.

“这种方法可能是心脏代谢疾病患者的下一个前沿，尽管目前有可用的治疗方法，但他们的风险仍然很高。”。

“With initial clinical validation, world-class scientific founders and investors, and an experienced board and leadership team, Marea is poised to become a premier cardiometabolic disease company,” said Jeffrey Tong, Ph.D., board member and partner, Third Rock Ventures. “We aim to accelerate a new generation of medicines, including MAR001, that treat key unaddressed drivers of cardiometabolic disease, potentially providing important new therapeutic options for millions of patients.”.

“凭借初步的临床验证，世界一流的科学创始人和投资者，以及经验丰富的董事会和领导团队，Marea有望成为一流的心脏代谢疾病公司，”Third Rock Ventures董事会成员兼合伙人Jeffrey Tong博士说。“我们的目标是加速开发包括MAR001在内的新一代药物，这些药物治疗心脏代谢疾病的关键未解决因素，可能为数百万患者提供重要的新治疗选择。”。

Targeting Cardiometabolic Diseases at their Source

从源头上针对心脏代谢疾病

Marea’s lead program, MAR001, is a monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby preferentially augmenting adipose tissue lipoprotein lipase (LPL) activity, MAR001 aims to lower remnant cholesterol, improve adipose tissue and metabolic function, and reduce cardiovascular events.

Marea的主要程序MAR001是一种针对ANGPTL4的单克隆抗体，ANGPTL4是一种在脂肪组织中高度表达的蛋白质。通过抑制ANGPTL4，从而优先增强脂肪组织脂蛋白脂肪酶（LPL）活性，MAR001旨在降低残余胆固醇，改善脂肪组织和代谢功能，并减少心血管事件。

Remnant cholesterol is carried by triglyceride-rich lipoproteins, is highly atherogenic, and drives cardiovascular events independent of classical risk factors like LDL cholesterol, diabetes or obesity1. There are currently no available targeted therapies to lower remnant cholesterol and improve metabolic function..

残余胆固醇由富含甘油三酯的脂蛋白携带，高度致动脉粥样硬化，并驱动心血管事件，而与LDL胆固醇，糖尿病或肥胖等经典危险因素无关1。目前还没有可用的靶向疗法来降低残余胆固醇并改善代谢功能。。

Human genetics has demonstrated ANGPTL4 as a highly promising therapeutic target to lower remnant cholesterol with loss of function alleles leading to remnant cholesterol clearance, improved triglyceride distribution, improved insulin sensitivity, and protection from both cardiovascular disease and type 2 diabetes all via an adipose specific mechanism..

人类遗传学已经证明，ANGPTL4是一种非常有前途的治疗靶点，可以通过脂肪特异性机制降低残留胆固醇，丧失功能等位基因，从而导致残留胆固醇清除，改善甘油三酯分布，改善胰岛素敏感性，以及预防心血管疾病和2型糖尿病。。

Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat (storage of triglycerides in tissues other than adipose tissue), and improved insulin sensitivity. MAR001 has demonstrated strong Phase 1 results and is in Phase 2 clinical development for adults with metabolic dysfunction..

MAR001的临床前模型显示甘油三酯，残余胆固醇和异位脂肪（甘油三酯在脂肪组织以外的组织中的储存）减少，胰岛素敏感性提高。MAR001已显示出强大的1期结果，目前正处于代谢功能障碍成年人的2期临床开发阶段。。

“ANGPTL4 human genetics shows the potential to essentially reverse the adipose dysfunction responsible for the metabolic syndrome- which is not adequately treated by current therapies including weight loss and LDL cholesterol treatment. More than five million cardiovascular patients in the U.S. alone have elevated remnant cholesterol putting them at risk for a heart attack,” said Ethan J.

EthanJ。

Weiss, M.D., co-founder and chief scientific officer of Marea. “MAR001 has the potential to provide unique benefit to these patients by correcting the underlying adipose dysfunction leading to both elevated remnant cholesterol and metabolic dysfunction.”.

Weiss，医学博士，Marea的联合创始人兼首席科学官。“MAR001有可能通过纠正导致残余胆固醇升高和代谢功能障碍的潜在脂肪功能障碍，为这些患者提供独特的益处。”。

“In a Phase 1 trial, a single dose of MAR001 significantly lowered remnant cholesterol levels and improved metabolic biomarkers. We are very excited about this compound’s potential,” said Maha Katabi, Ph.D., general partner, Sofinnova Investments. “Led by renowned experts in genetics and cardiometabolic diseases, Marea is well positioned to advance MAR001 and other pipeline programs, potentially unlocking a new era in cardiovascular care.”.

Sofinnova Investments的普通合伙人Maha Katabi博士说：“在第一阶段试验中，单剂量的MAR001显着降低了残余胆固醇水平并改善了代谢生物标志物。我们对这种化合物的潜力感到非常兴奋。”。“由遗传学和心脏代谢疾病领域的著名专家领导，Marea处于推进MAR001和其他管道项目的良好位置，有可能开启心血管护理的新时代。”。

Marea is also advancing a pipeline of additional candidates aimed to address additional untapped nodes driving cardiometabolic diseases.

Marea还正在推进一系列其他候选人，旨在解决驱动心脏代谢疾病的其他未开发节点。

Management and Organization

管理和组织

Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in human genetics, adipocyte biology and cardiometabolic disease drug development.

。

Marea founders include:

Marea创始人包括：

Charles Homcy, M.D., partner emeritus, Third Rock Ventures

Charles Homcy，医学博士，第三摇滚风险投资公司名誉合伙人

Sir Stephen O’Rahilly, M.D., FRS, professor of clinical biochemistry and medicine, University of Cambridge

剑桥大学临床生物化学与医学教授、医学博士斯蒂芬·奥拉希利爵士

Joshua Rabinowitz, M.D., Ph.D., professor of chemistry & integrative genomics, Princeton University

Joshua Rabinowitz，医学博士，博士，普林斯顿大学化学与整合基因组学教授

Ethan J. Weiss, M.D., chief scientific officer

医学博士伊桑·J·维斯（EthanJ.Weiss），首席科学官

Marea management team members include:

Marea管理团队成员包括：

Christine Garrett, Ph.D., chief strategy officer

首席战略官Christine Garrett博士

Mark Joing, MBA, chief development operations officer

Mark Joing，MBA，首席开发运营官

Josh Lehrer, M.D., M.Phil., FACC, chief executive officer

Josh Lehrer，医学博士，M.Phil，FACC，首席执行官

Ethan J. Weiss, M.D., scientific founder and chief scientific officer

医学博士伊桑·J·维斯（EthanJ.Weiss），科学创始人兼首席科学官

Marea board members include:

Marea董事会成员包括：

Ted Love, M.D., chairman, former president and chief executive officer of Global Blood Therapeutics (acquired by Pfizer) and chairman, Biotechnology Innovation Organization (BIO)

Ted Love，医学博士，全球血液疗法（被辉瑞收购）主席、前总裁兼首席执行官，生物技术创新组织（BIO）主席

Antoine Boulanger, Ph.D., principal, Forbion

Antoine Boulanger博士，Forbion校长

Jung Choi, MBA, entrepreneur in residence, Third Rock Ventures

Jung Choi，MBA，常驻企业家，Third Rock Ventures

Chris Garabedian, venture portfolio manager, Perceptive Advisors

Chris Garabedian，风险投资组合经理，敏锐的顾问

Maha Katabi, Ph.D., general partner, Sofinnova Investments

Maha Katabi博士，Sofinnova Investments普通合伙人

Josh Lehrer, M.D., M.Phil., FACC, chief executive officer

Josh Lehrer，医学博士，M.Phil，FACC，首席执行官

Aaron Royston, M.D., managing partner, venBio

Aaron Royston，医学博士，venBio管理合伙人

Jeffrey Tong, Ph.D., partner, Third Rock Ventures

Jeffrey Tong博士，Third Rock Ventures合伙人

“With its focused scientific approach and differentiated first-in-class development programs, Marea has the potential to become a leading company in the cardiometabolic disease space,” said Dr. Love. “I am thrilled to partner with this talented board and management team to advance MAR001 and other programs for patients who are in need of breakthrough cardiometabolic disease therapies.”.

Love博士说：“凭借其专注的科学方法和一流的差异化发展计划，Marea有潜力成为心脏代谢疾病领域的领先公司。”。“我很高兴能与这个才华横溢的董事会和管理团队合作，为需要突破性心脏代谢疾病治疗的患者推进MAR001和其他项目。”。

About Marea

关于大海

Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development to lower remnant cholesterol in adults with metabolic dysfunction and high risk for cardiovascular disease.

Marea Therapeutics是一家临床阶段的生物技术公司，利用人类遗传学的最新进展开发一流的下一代心脏代谢疾病药物。该公司的主导项目MAR001正在进行第二阶段临床开发，以降低代谢功能障碍和心血管疾病高风险成年人的残余胆固醇。

Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X..

。要了解更多信息，请访问www.mareatx.com，并在LinkedIn和X上关注我们。。

1 https://doi.org/10.1161/CIRCIMAGING.121.012615Circulation: Cardiovascular Imaging. 2021;14:e012615

1https://doi.org/10.1161/CIRCIMAGING.121.012615Circulation:心血管成像。2021年；14： e012615